RA Capital Management

What RA Capital Management does

RA Capital Management, L.P. is a privately-held, Boston-based multi-stage investment manager founded in 2001, dedicated to evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm operates across the full capital lifecycle — from company creation and seed funding through public-market positions — and explicitly extends its thesis into a Planetary Health vertical addressing climate and sustainability. RA Capital generates revenue through three streams: management fees on its private and public investment funds, carried interest from successful portfolio exits, and SPAC sponsor economics via its three Research Alliance Corporation vehicles (I, II, III), with RACC having completed a $75M Nasdaq IPO in May 2026.

The firm's core differentiator is TechAtlas, an internal think-tank division that systematically analyzes scientific and clinical data from academic literature and thousands of industry product development programs to generate proprietary investment conviction. The Raven healthcare incubator creates new biotech companies from inception, providing operational support, executive talent, and capital — with portfolio incubations including NexCure and the Sera Medicines antibody accelerator, whose fifth subsidiary Memento Medicines closed a $93M Series A in June 2026. RA Capital also operates the RApport knowledge publication, RA University educational platform (including the Biotech Unveiled course in partnership with NPLB), and the S2S China Symposium co-hosted with Qiming Venture Partners, signaling a formal China expansion.

The firm is led by Managing Partners Peter Kolchinsky (PhD virology, Harvard) and Rajeev Shah, with a senior team including a CFO, General Counsel, CIO, Chief Compliance Officer, Chief People Officer, multiple Partners and Managing Directors across venture and public equity teams, and dedicated heads of TechAtlas, Infectious Disease, IT/Cybersecurity, Trading, Engineering & AI, and Family Office services. The firm manages a globally diversified portfolio across therapeutic areas and has a documented exit track record including Point Biopharma ($1.4B, Eli Lilly), 89bio ($3.5B, Roche), Metsera ($10B, Pfizer), and Capstan Therapeutics (acquired by AbbVie in 2025).

Name

RA Capital Management

Legal name

RA Capital Management, L.P.

Website

https://www.racap.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

RA Capital Management is a Boston-based multi-stage investment manager specializing in evidence-based investing across public and private healthcare, life science, and planetary health companies, supported by its TechAtlas research division and Raven company-creation incubator.

Ownership category

akta.pro rank

Product category

Healthcare and Life Sciences Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282), Investors, Nec (6799)

akta.pro primary industry

Institutional Separate Accounts & SMAs (Mandates) (FSAAAGAL)

Keywords

• Healthcare venture capital
• Life sciences investing
• Biotech investment management
• Pharmaceutical equity research
• Planetary health investing

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Management Fees: RA Capital earns management fees from its managed investment funds, both public and private vehicles.
2. Carried Interest / Performance Fees: The firm earns carried interest (performance-based fees) from successful portfolio company exits across its venture and public investment strategies.
3. SPAC Sponsorships: RA Capital sponsors Special Purpose Acquisition Companies (Research Alliance Corp I, II, III) that seek business combinations in healthcare, generating sponsor economics upon mergers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

RA Capital Management is a multi-stage investment manager that forms, funds, and supports healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm deploys capital across public and private markets, from discovery through commercialization, sources deals through its proprietary TechAtlas research division, creates companies via its Raven incubator, and sponsors SPAC vehicles (Research Alliance Corp I, II, III) for taking private healthcare companies public.

Product overview

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in healthcare and life science companies. The firm operates several interconnected platforms: TechAtlas serves as an internal research think tank analyzing scientific and clinical data across disease indications; Raven is their healthcare incubator that creates new biotech companies; Sera Medicines is their antibody accelerator subsidiary; and the firm manages SPAC vehicles like Research Alliance Corporation III for acquiring healthcare companies. Their portfolio spans drugs, medical devices, diagnostics, services, and research tools across all development stages. The firm also maintains RApport as a knowledge-sharing platform and RA University for biotech education.

Differentiator

Problem solved

Functional benefit

Brands

• TechAtlas: Internal think tank division that analyzes scientific and clinical data from academic literature and industry product development programs
• Raven
• Sera Medicines
• Research Alliance Corporation III

Products and services

• TechAtlas An internal research division and competitive intelligence platform that analyzes scientific and clinical data from academic literature and thousands of industry product development programs to support evidence-based investment decisions and competitive landscape analysis for drugs and medical devices across a range of disease indications.
• Raven Healthcare Incubator RA Capital's healthcare incubator that creates new biotech companies from concept through clinical development, providing operational support, executive talent, corporate development services, and capital to build companies from inception.
• Venture Investing RA Capital's venture investing platform that works with founders to build companies from lab concept through clinical development and commercialization, deploying capital across all stages from discovery through IPO and beyond.
• Research Alliance Corporation III (RACC) SPAC A special purpose acquisition company (SPAC) sponsored by RA Capital Management seeking business combinations in the healthcare or healthcare-related industries, with explicit interest in Chinese biotech companies.
• Sera Medicines Antibody Accelerator An antibody accelerator subsidiary established in collaboration with RA Capital in 2023, which has financed multiple subsidiary companies including Memento Medicines.
• RApport Knowledge Platform RA Capital's platform for biotech and planetary health insight and opinion, featuring articles, presentations, and books with insights into biotech, healthcare, and investing, edited by Chris Morrison.
• RA University Free, intensive courses on advanced topics in biotech business, including the flagship course Biotech Unveiled offered in partnership with NPLB (Never Pink? Let's Build?).

Quantifiable outcome

• Point Biopharma acquired by Eli Lilly for $1.4 billion
• +5 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Qiming Venture PartnerscoreStrategic or Co-development Partner · 20 April 2026RA Capital co-hosts the S2S (Start-up to Summit) China Symposium with Qiming Venture Partners, scheduled for October 15, 2026 in Hangzhou, China, aimed at connecting top Chinese scientists with major biotech investors.

Scale indicators31 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• OrbiMed: One of the largest dedicated healthcare investment managers globally, running private equity, venture, and royalty/credit strategies across stages. Directly comparable to RA Capital given multi-strategy healthcare focus, late-stage crossover deals (Windward Bio), and breadth across biotech, medtech, and diagnostics.
• ARCH Venture Partners: Pioneering life sciences venture firm that co-leads and participates in large clinical-stage financings (Ollin Biosciences $330M Series B with RA Capital). Comparable as a science-led VC that backs transformative biotech platforms and partners with strategic investors.
• Perceptive Advisors: Healthcare-focused crossover/hedge fund that invests in both private rounds and public biotech equities; co-anchored Solid Biosciences' $240M placement with RA Capital. Closely comparable given dual private/public healthcare strategy and willingness to lead large PIPEs (Diamyd Medical, Solid Biosciences).
• Frazier Life Sciences: Dedicated life sciences venture firm that led cAMPfield Therapeutics' $180M Series A with RA Capital participation. Comparable as a stage-agnostic healthcare-only investor backing clinical-stage therapeutics.
• Atlas Venture: Early-stage life sciences venture firm that builds biotech companies from academic science; comparable to RA Capital's Raven incubator and Sera Medicines accelerator model of company creation, though with an earlier stage focus.
• 5AM Ventures: Science-driven early-stage venture firm in healthcare. Comparable as a dedicated life sciences investor with similar thesis-driven, evidence-based diligence approach and broad stage reach from seed through IPO.
• MPM Capital: Dedicated healthcare investment firm managing both early-stage venture and impact/public-equity strategies. Sarah Reed, RA Capital's General Counsel, was previously MPM's COO & GC, underscoring the direct comparison on model, mandate, and stage coverage.
• BVF Partners: Healthcare-focused crossover fund that co-led Contrace's $92.5M Series B with RA Capital and participates widely in biotech PIPEs (Q32 Bio). Comparable as a biotech-only specialist with multi-strategy public and private exposure.
• Forbion: European-headquartered dedicated life sciences venture firm; co-led Memento Medicines' $93M Series A with RA Capital. Comparable as a multi-stage biotech investor with similar clinical-stage focus and participation in mega-rounds.

Broad incumbents

• Novo Holdings: Large Danish-backed holding company with a dedicated life sciences venture arm that participated in cAMPfield's Series A alongside RA Capital. Comparable as a large-scale, institutionally backed healthcare investor, though with broader activities beyond venture capital.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/racapital
• LinkedInlinkedin.com/company/ra-capital-management-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments588 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RA Capital Management